Translational research engine for longevity

Human evidence that sharpens your next move.

Exploratory human proof-of-mechanism for longevity companies.

Phase 2 is where value is won or lost.

2×
Clearing Phase 2 doubles a company's valuation.
Michaeli et al., 2022; BayBridgeBio.
29%
of drugs clear Phase 2, the lowest success rate of all phases.
BIO / Informa, Clinical Development Success Rates 2011-2020.
80×
Rise in the inflation-adjusted cost to develop a new drug since 1950.
Scannell et al., Nature Reviews Drug Discovery, 2012.
More to come